POMC and prostate cancer: Potent 17α-hydroxylase inhibition by the prostate cancer drug abiraterone leads to impaired cortisol production with subsequent feedback activation, increased ACTH levels, accumulation of the mineralocorticoids 11-DOC and corticosterone, water retention, hypertension, and hypokalemia (Attard et al., 2012).